Insulin-secreting L-cells for the treatment of insulin-dependent diabetes.

Biochemical and Biophysical Research Communications
Heather Bara, A Sambanis

Abstract

Cell-based treatments for insulin-dependent diabetes (IDD) may provide more physiologic regulation of blood glucose levels than daily insulin injections, thereby reducing the occurrence of secondary complications associated with diabetes. An autologous cell source is especially attractive for regulatory and ethical reasons in addition to eliminating the need for immunosuppression. This study uses non-beta-cells, genetically modified for physiologic insulin secretion. Enteroendocrine L-cells, exhibit regulated secretion in response to physiologic stimuli and their endogenous products are fully compatible with prandial metabolism. Murine GLUTag L-cells were transfected with a plasmid co-expressing human insulin and neomycin resistance and the stable cell line, GLUTag-INS, was established. Secretion properties of GLUTag-INS cells were investigated in vitro through induced secretion tests using meat hydrolysate or 3-isobutyl-1-methylxanthine and forskolin as secretagogues. GLUTag-INS cells rapidly co-secreted recombinant insulin and endogenous glucagon-like peptide in response to metabolic cues from the surrounding medium and demonstrated efficient processing of proinsulin to insulin.

References

Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·G P SchwartzP G Katsoyannis
Jan 1, 1996·The Journal of Clinical Investigation·J SchirraB Göke
Dec 22, 1999·Endocrine Reviews·T J Kieffer, J F Habener
Nov 18, 2000·Gene Therapy·P M Thulé, J M Liu
Aug 28, 2002·Diabetes·Frank Reimann, Fiona M Gribble
Mar 28, 2003·Biochemical and Biophysical Research Communications·Shiue-Cheng Tang, Athanassios Sambanis
Oct 28, 2003·Human Gene Therapy·Darin E OlsonPeter M Thulé
Jun 17, 2004·Experimental Diabesity Research·P VagueM Tsimaratos
Sep 1, 2006·Seminars in Interventional Radiology·Brian Funaki

❮ Previous
Next ❯

Citations

Aug 17, 2011·Diabetes, Obesity & Metabolism·E Tudurí, T J Kieffer
Sep 20, 2012·BMC Biotechnology·Zalinah AhmadAbdul Rahman Omar
Mar 21, 2012·Journal of Diabetes·Eva TuduríTimothy J Kieffer
Nov 19, 2011·Biotechnology and Bioengineering·Kiranmai DurvasulaAthanassios Sambanis
May 18, 2016·Journal of Diabetes Investigation·Majid MojibianTimothy J Kieffer
Jul 23, 2014·Journal of Tissue Engineering and Regenerative Medicine·Aubrey R Tiernan, Athanassios Sambanis
Oct 12, 2014·Experimental Cell Research·Aubrey R TiernanAthanassios Sambanis
Jun 14, 2014·Transplantation·Aubrey R TiernanAthanassios Sambanis
Feb 11, 2010·Journal of Diabetes Science and Technology·Heather BaraAthanassios Sambanis
Jun 13, 2019·Journal of the Endocrine Society·Wendy M McKimpson, Domenico Accili
Oct 27, 2020·Frontiers in Endocrinology·Julia HanchardSteffen-Sebastian Bolz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.